RESEARCH MONOGRAPH · KDC-MN-375

Sarcosine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

77/100

Underrated glycine reuptake inhibitor with the cleanest schizophrenia adjunct data of the bunch

Honestly sarcosine deserves more attention than it gets. It's N-methylglycine. A natural metabolite of glycine, sitting one methyl group off from a textbook amino acid. The interesting part is that it weakly inhibits GlyT1, the glycine transporter on glial cells around glutamatergic synapses. Block GlyT1, glycine accumulates in the synaptic cleft, NMDA receptor co-agonist site sees more occupancy, NMDA signaling gets a nudge upward. That's the whole pharmacology in one paragraph and it's surprisingly clean.

Here's the thing: the Tsai group in Taiwan has run the most consistent adjunct trials of any NMDA-modulating strategy. Multiple small RCTs at 1 to 2 g/day with stable antipsychotics, and they keep showing improvement in negative symptoms and PANSS general scores. Not huge effects. But effects you can actually find. Bitopertin from Roche, a stronger GlyT1 inhibitor, missed phase 3, which dampened enthusiasm for the whole class. The sarcosine data outlived bitopertin's failure, which says something.

What we like is how sane the mechanism is. You're not jamming the NMDA receptor open with a partial agonist that you have to titrate carefully. You're letting the endogenous co-agonist do its job a little longer. The receptor still gates on glutamate. That's why the safety profile in the trials has been boring, which is what you want.

Sourcing is straightforward, sarcosine is dirt cheap to synthesize, and HPLC purity from any decent supplier should be 99 percent plus. The catch is that it's also found in protein supplements and is a substrate for sarcosine oxidase, so handling and storage are normal amino acid territory.

One thing people miss: there's an OCD line of evidence too. Small open-label work suggesting GlyT1 modulation helps in treatment-resistant cases. Mechanistically that tracks because OCD and schizophrenia share some glutamatergic dysregulation themes. The data is preliminary but the direction is interesting.

For research applications it's the cleanest GlyT1 tool compound available, and the cost-to-evidence ratio is excellent. Slept on for sure.

Evidence: 65
Mechanism: 80
Reliability: 70
Safety: 82
Sourcing: 88
Value: 88
Signal: 70
Staying power: 72

Plain-language summary Intrigue 60 / 100

Sarcosine is an N-methylated version of the amino acid glycine, made naturally in your body. It blocks the GlyT1 transporter that normally clears glycine from the synapse, so glycine builds up near NMDA receptors and boosts their function (glycine is the other co-agonist alongside D-serine). This is essentially a back-door way to enhance NMDA signaling without giving D-serine directly. Phase 2 trials added it to standard antipsychotics in schizophrenia and to antidepressants in depression, with small to moderate effects on negative symptoms and mood. Bitopertin, a more potent selective GlyT1 inhibitor, ran the same play but failed phase 3, which tempered enthusiasm for the whole approach. Reference compound for glycine-transporter pharmacology. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Glycine reuptake inhibitor (GlyT1)

N-methylglycine; an endogenous methylglycine that inhibits glycine reuptake at GlyT1, elevating synaptic glycine.

Abstract

Sarcosine (N-methylglycine; CAS 107-97-1; molecular formula C3H7NO2; molecular weight 89.09) is an endogenous N-methylated derivative of glycine and a competitive substrate of the glycine transporter type 1 (GlyT1). Pharmacologically, sarcosine inhibits glycine reuptake at GlyT1, elevating extracellular glycine concentrations near NMDA receptors and consequently enhancing NMDA receptor function via the glycine co-agonist site. The mechanism complements direct D-serine administration. Phase 2 trials in schizophrenia (as adjunct to risperidone or olanzapine) and major depressive disorder have shown small to moderate effects on negative symptoms and depressive symptoms. Plasma half-life is approximately 7 hours; the compound is well tolerated. The selective GlyT1 inhibitor bitopertin (RG1678) was developed as a more potent alternative but failed phase 3 trials. Used as the canonical GlyT1 substrate inhibitor in NMDA receptor research.

Mechanism of action

Competitive substrate of glycine transporter type 1 (GlyT1); elevates extracellular glycine near NMDA receptors and enhances NMDA function via glycine co-agonist site.

Reported research dose ranges

Clinical trials 1 to 2 g in the published literature.

References

Tsai G, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004.
Lane HY, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia. Arch Gen Psychiatry 2005.
Huang CC, et al. Sarcosine as add-on therapy in major depressive disorder. J Clin Psychiatry 2013.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-375

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Sarcosine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs